I will be speaking in Iselin, NJ and Portland, Oregon during the upcoming PerkinElmer tour.

Evidence from recent FDA Warning Letters and 483’s issued to dietary supplement firms under current good manufacturing practice regulations (21 CFR 111 cGMP’s) indicates that FDA is stepping up its focus on laboratories and testing.  This presentation outlines the common laboratory compliance problems FDA is finding during inspections, and shows how those issues can easily escalate into Warning Letters if not properly corrected.

Details are here: http://web2.perkinelmer.com/INTour-2013

Hope to see you there!